Leach originally took over as COO in 2022. He previously served as chief technology officer (CTO), starting in 2018. In that role, he led the company’s research, product development, product management and engineering departments. He joined the company in 2004 to lead the development of sensor electronics for its first commercial continuous glucose monitor (CGM) system.
Leach has spent 21 years at the company, leading teams responsible for developing multiple generations of CGMs. Those include the current-generation G7 and Stelo over-the-counter offerings.
As COO, he provides end-to-end responsibility for product development and oversight of executive leadership functions. That includes global operations, R&D, quality management, regulatory and medical affairs. Now, as president as well, he takes on the additional responsibility of overseeing corporate development and strategy efforts at Dexcom.
Kevin Sayer, Dexcom chair and CEO, said he has “no doubt” in Leach’s ability to continue success with the promotion.
“My confidence in Dexcom’s future opportunities and the quality of our leadership have never been greater,” said Sayer. “Jake has strengthened the company’s ability to innovate and achieve ambitious goals that will benefit the future of metabolic health.”
Leach spoke of his new role with optimism as well.
“There are few companies in the world with an opportunity to address the greatest challenges in global health while simultaneously benefiting our customers, shareholders and communities,” said Leach. “Taking on the role of president at this moment in our company’s history is incredibly exciting, and I look forward to working with Kevin to lead Dexcom into a bright future.”
